JP2008518904A - ６−［２−（メチルカルバモイル）フェニルスルファニル］−３−ｅ−［２−（ピリジン−２−イル）エテニル］インダゾールの多形体形態 - Google Patents

６−［２−（メチルカルバモイル）フェニルスルファニル］−３−ｅ−［２−（ピリジン−２−イル）エテニル］インダゾールの多形体形態 Download PDF

Info

Publication number
JP2008518904A
JP2008518904A JP2007538541A JP2007538541A JP2008518904A JP 2008518904 A JP2008518904 A JP 2008518904A JP 2007538541 A JP2007538541 A JP 2007538541A JP 2007538541 A JP2007538541 A JP 2007538541A JP 2008518904 A JP2008518904 A JP 2008518904A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
polymorph
acceptable salt
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007538541A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008518904A5 (enExample
Inventor
マーシャル ハート リアン
スティーブン カニア ロバート
オウルレット マイケル
ピング ウ ゼン
イェ キアング
エドワード ズーク スコット
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2008518904A publication Critical patent/JP2008518904A/ja
Publication of JP2008518904A5 publication Critical patent/JP2008518904A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2007538541A 2004-11-02 2005-10-21 ６−［２−（メチルカルバモイル）フェニルスルファニル］−３−ｅ−［２−（ピリジン−２−イル）エテニル］インダゾールの多形体形態 Pending JP2008518904A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62466504P 2004-11-02 2004-11-02
PCT/IB2005/003312 WO2006048751A1 (en) 2004-11-02 2005-10-21 Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole

Publications (2)

Publication Number Publication Date
JP2008518904A true JP2008518904A (ja) 2008-06-05
JP2008518904A5 JP2008518904A5 (enExample) 2008-10-09

Family

ID=35538878

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007538541A Pending JP2008518904A (ja) 2004-11-02 2005-10-21 ６−［２−（メチルカルバモイル）フェニルスルファニル］−３−ｅ−［２−（ピリジン−２−イル）エテニル］インダゾールの多形体形態

Country Status (14)

Country Link
US (1) US20060094763A1 (enExample)
EP (1) EP1819696A1 (enExample)
JP (1) JP2008518904A (enExample)
KR (1) KR20070060145A (enExample)
AR (1) AR051945A1 (enExample)
AU (1) AU2005300317A1 (enExample)
BR (1) BRPI0517924A (enExample)
CA (1) CA2586177A1 (enExample)
IL (1) IL182580A0 (enExample)
MX (1) MX2007005273A (enExample)
RU (1) RU2007116150A (enExample)
TW (1) TW200630356A (enExample)
WO (1) WO2006048751A1 (enExample)
ZA (1) ZA200702976B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026517320A (ja) * 2024-04-12 2026-05-29 スカイ・セラピューティクス・カンパニー・リミテッド アキシチニブの新規分子会合体

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080274192A1 (en) * 2005-05-19 2008-11-06 Pfizer Inc. Pharmaceutical Compositions Comprising an Amorphous Form of a Vegf-R-Inhibitor
CN101679356A (zh) 2007-04-05 2010-03-24 辉瑞产品公司 适用于治疗哺乳动物异常细胞生长的6-[2-（甲基-氨甲酰基）苯基硫基]-3-e-[2-(吡啶-2-基)乙烯基]吲唑的晶型
TW201531309A (zh) 2011-09-30 2015-08-16 Pfizer Ｎ-甲基-２-〔３-（（ｅ）-２-吡啶-２-基-乙烯基）-１ｈ-吲唑-６-基硫烷基〕苯甲醯胺之藥學組成物
JP2014533262A (ja) 2011-11-11 2014-12-11 ファイザー・インク 慢性骨髄性白血病を治療するためのｎ−メチル−２−［３−（（ｅ）−２−ピリジン−２−イル−ビニル）−１ｈ−インダゾール−６−イルスルファニル］−ベンズアミド
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CN104140414B (zh) * 2013-05-07 2018-12-11 江苏豪森药业集团有限公司 阿昔替尼晶型的制备方法
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
US10570202B2 (en) 2014-02-04 2020-02-25 Pfizer Inc. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
KR20170132171A (ko) 2015-02-26 2017-12-01 메르크 파텐트 게엠베하 암 치료를 위한 ｐｄ­１ ／ ｐｄ­ｌ１ 저해제
WO2016178150A1 (en) * 2015-05-05 2016-11-10 Shilpa Medicare Limited Novel polymorphs of axitinib
RU2766890C2 (ru) 2015-06-16 2022-03-16 Мерк Патент Гмбх Комбинированные способы лечения антагонистами pd-l1
BR112019006504A2 (pt) 2016-10-06 2019-06-25 Pfizer Inc. regime de dosagem de avelumabe para o tratamento de câncer
WO2020003196A1 (en) * 2018-06-28 2020-01-02 Alembic Pharmaceuticals Limited Pharmaceutical composition of axitinib
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
ES2982700T3 (es) 2019-04-18 2024-10-17 Synthon Bv Proceso para preparar axitinib, proceso para purificar el producto intermedio 2-((3-yodo-1H-indazol-6-il)tio)-n-metilbenzamida, proceso para purificar axitinib a través de la sal HCI de axitinib, forma sólida de la sal HCI de axitinib
EA202193065A1 (ru) 2019-05-09 2022-03-02 Синтон Б.В. Фармацевтическая композиция, содержащая акситиниб
CA3171563A1 (en) 2020-03-25 2021-09-30 Charles D. Blizzard Ocular implant containing a tyrosine kinase inhibitor
CN113943271B (zh) * 2020-07-15 2023-11-14 鲁南制药集团股份有限公司 一种阿昔替尼晶型及其制备方法
CN112174933A (zh) * 2020-08-07 2021-01-05 天津理工大学 一种阿西替尼富马酸盐的新晶型及其制备方法
CN114685437B (zh) * 2020-12-25 2022-12-09 鲁南制药集团股份有限公司 阿昔替尼与糖精共晶
CN114685436B (zh) * 2020-12-25 2022-12-02 鲁南制药集团股份有限公司 阿昔替尼糖精共晶水合物
CN114685431B (zh) * 2020-12-26 2022-11-29 鲁南制药集团股份有限公司 一种阿昔替尼柠檬酸盐晶型
CN114685438B (zh) * 2020-12-28 2023-06-13 鲁南制药集团股份有限公司 一种阿昔替尼苹果酸新盐
CN114685433B (zh) * 2020-12-28 2022-11-25 鲁南制药集团股份有限公司 一种阿昔替尼香草酸共晶盐及其制备
CN114685432B (zh) * 2020-12-28 2022-11-25 鲁南制药集团股份有限公司 阿昔替尼盐晶型及其制备方法
CN114685435B (zh) * 2020-12-28 2023-01-31 鲁南制药集团股份有限公司 阿昔替尼马来酸盐晶型及其制备
IL315262A (en) 2022-03-03 2024-10-01 Pfizer Multiple specific antibodies related to IL-4, IL-13 and/or TSLP and their uses
EP4282415A1 (en) 2022-05-26 2023-11-29 Genepharm S.A. A stable tablet composition of axitinib
JP2026520094A (ja) * 2023-04-11 2026-06-22 オキュラ セラピューティクス，インコーポレイテッド アキシチニブ多形ｉｖを含む眼科インプラント
KR20250108329A (ko) 2024-01-08 2025-07-15 (주)유케이케미팜 엑시티닙의 제조방법
WO2025157389A1 (en) 2024-01-22 2025-07-31 Iomx Therapeutics Ag Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors
KR102838026B1 (ko) * 2024-04-30 2025-07-28 주식회사 스카이테라퓨틱스 액시티닙 신규 분자 회합체를 포함하는 점안 조성물 및 이의 제조방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503481A (ja) * 1999-07-02 2003-01-28 アゴウロン・ファーマスーティカルス・インコーポレーテッド インダゾール及びプロテインキナーゼ阻害のためのその使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503481A (ja) * 1999-07-02 2003-01-28 アゴウロン・ファーマスーティカルス・インコーポレーテッド インダゾール及びプロテインキナーゼ阻害のためのその使用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026517320A (ja) * 2024-04-12 2026-05-29 スカイ・セラピューティクス・カンパニー・リミテッド アキシチニブの新規分子会合体

Also Published As

Publication number Publication date
BRPI0517924A (pt) 2008-10-21
AU2005300317A1 (en) 2006-05-11
EP1819696A1 (en) 2007-08-22
RU2007116150A (ru) 2008-11-10
MX2007005273A (es) 2007-07-19
KR20070060145A (ko) 2007-06-12
IL182580A0 (en) 2007-07-24
CA2586177A1 (en) 2006-05-11
TW200630356A (en) 2006-09-01
WO2006048751A1 (en) 2006-05-11
US20060094763A1 (en) 2006-05-04
ZA200702976B (en) 2008-08-27
AR051945A1 (es) 2007-02-21

Similar Documents

Publication Publication Date Title
JP6013551B2 (ja) ８−フルオロ−２−｛４−［（メチルアミノ）メチル］フェニル｝−１，３，４，５−テトラヒドロ−６Ｈ−アゼピノ［５，４，３−ｃｄ］インドール−６−オンの塩および多形体
US20060094763A1 (en) Polymorphic forms of 6-[2-(methylcarbomoyl) phenyl sulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole
US20060167056A1 (en) Polymorphs of {5-[3-(4,6-Difluoro-1H-benzoimidazol-2-yl)-1H-indazol-5-yl)-4-methyl-pyridin-3-ylmethyl}-ethyl-amine
CA2682859C (en) Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl)indazole for treatment of abnormal cell growth in mammals
CN101048398A (zh) 6－[2－(甲基氨甲酰基)苯基硫烷基]－3－e－[2－(吡啶－2－基)乙烯基]吲唑的多晶型
HK40091859A (en) Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one
HK40022061A (en) Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one
HK1234044B (en) Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
HK1234044A1 (en) Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
HK1109146A (en) Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole
HK1176617B (en) Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
HK1116483A1 (en) Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
HK1116483B (en) Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080821

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080821

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20080821

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20080930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081027

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090323